IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v39y2021i6d10.1007_s40273-021-01021-w.html
   My bibliography  Save this article

The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder

Author

Listed:
  • Alix Arnaud

    (Sage Therapeutics, Inc)

  • Ellison Suthoff

    (Sage Therapeutics, Inc)

  • Rita M. Tavares

    (Boston Strategic Partners, Inc)

  • Xuan Zhang

    (Boston Strategic Partners, Inc)

  • Aditi J. Ravindranath

    (Boston Strategic Partners, Inc)

Abstract

Objectives Major depressive disorder (MDD) is a common and serious disorder with significant impact on patients and families. The goal of this retrospective cohort study was to determine the economic burden among patients with MDD stratified by number of treatment lines needed for episode resolution. Methods Truven Health Analytics MarketScan® claims data were used to identify US patients (≥ 18 years) who were diagnosed with MDD and started on an antidepressant between 2013 and 2017. A generalized linear model estimated direct and employment-related costs for the first 12 months following initiation of treatment across cohorts with increasing number of lines of MDD pharmacotherapy. Analyses were adjusted for demographics and clinical factors. Results A total of 73,597 patients with MDD comprising the commercial (n = 66,459) and Medicare (n = 7138) populations met selection criteria. Patients who completed treatment for their episode with a single line of antidepressant had the lowest total adjusted direct costs (commercial $9975; Medicare $14,628) followed by those who completed with two lines (commercial $11,723; Medicare $15,526) and those treated with three or more lines of antidepressant regimens (commercial $21,259; Medicare $20,964). Patients who completed treatment with two lines as opposed to one incurred significantly higher direct costs (commercial +$1748, p

Suggested Citation

  • Alix Arnaud & Ellison Suthoff & Rita M. Tavares & Xuan Zhang & Aditi J. Ravindranath, 2021. "The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder," PharmacoEconomics, Springer, vol. 39(6), pages 691-706, June.
    • Handle: RePEc:spr:pharme:v:39:y:2021:i:6:d:10.1007_s40273-021-01021-w
    DOI: 10.1007/s40273-021-01021-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-021-01021-w
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-021-01021-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. David Proudman & Paul Greenberg & Dave Nellesen, 2021. "The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers," PharmacoEconomics, Springer, vol. 39(6), pages 619-625, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:6:d:10.1007_s40273-021-01021-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.